INBRX-109 + Placebo
Phase 2Active 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Conventional Chondrosarcoma
Conditions
Conventional Chondrosarcoma
Trial Timeline
Sep 23, 2021 → Dec 1, 2026
NCT ID
NCT04950075About INBRX-109 + Placebo
INBRX-109 + Placebo is a phase 2 stage product being developed by Inhibrx Biosciences for Conventional Chondrosarcoma. The current trial status is active. This product is registered under clinical trial identifier NCT04950075. Target conditions include Conventional Chondrosarcoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04950075 | Phase 2 | Active |
Competing Products
1 competing product in Conventional Chondrosarcoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD6738 | AstraZeneca | Phase 1 | 33 |